NP2D has been established as an international, interdisciplinary exchange platform for specialists and decision makers involved in major overlapping areas of Pharma R&D such as: Peptidic hormones, Toxins and Antimicrobial peptides.

NP2D aims to bring together:

• Academic and Industrial Research Directors
• Development and Production Directors from the Pharma and Biotech industry
• Service providers and Contract Research Organisations
• Suppliers of technology and instrumentation
• Venture capitalists

Located in Zermatt, limited in size to 150 persons, and offering ample time for social activities, the congress is designed to promote fruitful interactions among the participants and above all, long-lasting relationships.

NP2D is offered as an attractive, all-included congress package at Zermatt’s prestigious five-star hotel “Seiler Hotel Mont Cervin”. Zermatt is at the foot of the majestic Matterhorn mountain in the Swiss Alps at an altitude of 1’620 m (5’315 ft). Participants will have the option to extend the stay in Zermatt at specially reduced rates.

The following people have confirmed their participation as plenary lecturers* and/or as members of the scientific committee: • Paul Alewood, University of Queensland, Australia • Alain Beck*, Centre d'Immunologie Pierre Fabre, France • Michael J. Brownstein*, J. Craig Venter Institute, USA • Philippe Bulet, Atheris Laboratories, Switzerland • George Chandy, University of California Irvine, USA • Patrick Garouste*, Debio Group, Lausanne, Switzerland • Alan Harvey*, Strathclyde Institute for Drug Research, Glasgow, UK  • Peter Hoffmann, Genzyme Pharmaceuticals, USA • Stephen B.H. Kent*, University of Chicago, USA  • André Ménez, CEA‑Saclay, France • John. P. Mayer*, Lilly Research Laboratories, Indianapolis, USA • George Miljanich*, Elan Pharmaceuticals Menlo Park, USA • Per Holse Mygind*, Novozymes A/S, Danemark • Dimitrios Noukakis, N!light, Switzerland • Jennifer Riggs-Sauthier*, Nektar Therapeutics, USA • Robin Offord, Geneva University, Switzerland • Michael Pennington, Bachem Bioscience, USA • Reto Stöcklin, Atheris Laboratories, Switzerland • Timothy Wells, Serono International, Switzerland • Geoffrey W. Tregear*, Howard Florey Institute, The University of Melbourne, Australia.